The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) is a huge mover today! About 963,501 shares traded hands or 879.35% up from the average. Vascular Biogenics Ltd (NASDAQ:VBLT) has risen 56.25% since April 26, 2016 and is uptrending. It has outperformed by 50.99% the S&P500.
The move comes after 6 months positive chart setup for the $148.98M company. It was reported on Nov, 29 by Barchart.com. We have $5.99 PT which if reached, will make NASDAQ:VBLT worth $11.92 million more.
Analysts await Vascular Biogenics Ltd (NASDAQ:VBLT) to report earnings on April, 4. They expect $-0.15 EPS, down 7.14% or $0.01 from last year’s $-0.14 per share. After $-0.12 actual EPS reported by Vascular Biogenics Ltd for the previous quarter, Wall Street now forecasts 25.00% negative EPS growth.
Vascular Biogenics Ltd (NASDAQ:VBLT) Ratings Coverage
Out of 5 analysts covering Vascular Biogenics (NASDAQ:VBLT), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $27.50 is the highest target while $8 is the lowest. The $17.13 average target is 208.65% above today’s ($5.55) stock price. Vascular Biogenics has been the topic of 8 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Tuesday, June 28 by H.C. Wainwright. The firm earned “Buy” rating on Friday, October 23 by Chardan Capital Markets. Chardan Capital Markets initiated Vascular Biogenics Ltd (NASDAQ:VBLT) rating on Monday, September 21. Chardan Capital Markets has “Buy” rating and $25 price target. The stock of Vascular Biogenics Ltd (NASDAQ:VBLT) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Mkt Outperform” rating on Monday, September 21 by JMP Securities. The rating was initiated by Piper Jaffray on Monday, November 9 with “Overweight”. Roth Capital maintained the shares of VBLT in a report on Monday, September 28 with “Buy” rating. Roth Capital maintained Vascular Biogenics Ltd (NASDAQ:VBLT) on Monday, August 24 with “Buy” rating.
According to Zacks Investment Research, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.”
More notable recent Vascular Biogenics Ltd (NASDAQ:VBLT) news were published by: Globenewswire.com which released: “Vascular Biogenics Ltd. Announces Pricing of $15 Million Underwritten Offering …” on November 03, 2015, also Globenewswire.com with their article: “Vascular Biogenics Ltd. Closes $24 Million Registered Direct Offering” published on June 16, 2016, Investorplace.com published: “Vascular Biogenics Ltd (VBLT) Stock Roars Higher on Cancer Trial” on June 06, 2016. More interesting news about Vascular Biogenics Ltd (NASDAQ:VBLT) were released by: Marketwatch.com and their article: “Virtual Stock Exchange” published on October 02, 2014 as well as Streetinsider.com‘s news article titled: “H.C. Wainwright Starts Vascular Biogenics Ltd (VBLT) at Buy” with publication date: June 28, 2016.
VBLT Company Profile
Vascular Biogenics Ltd., incorporated on January 31, 2000, is a clinical-stage biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. The Company’s lead product candidate, VB-111(ofranergene obadenovec), is a gene biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule that demonstrated efficacy in reducing vascular inflammation in a Phase II sub-study in psoriatic patients with cardiovascular risk.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.